ENTITY – Talk Bio

Roche’s Oral SERD Giredestrant Delays Early Breast Cancer Recurrence in Late-Stage Trial

9 hours ago talkbio0Tagged Adjuvant Therapy, Disease-Free Survival, ER-positive, giredestrant, HER2-negative, Malignant neoplasm of breast, Oral SERD, Phase 3 trial, recurrence prevention, Roche (company)

Roche; oral SERD; giredestrant; Phase 3 trial; early breast cancer; ER-positive; HER2-negative; disease-free survival; adjuvant therapy; recurrence prevention

Jazz and Zymeworks Bispecific Antibody Zanidatamab Delivers Practice-Changing Results in Stomach Cancer Study

13 hours ago talkbio0Tagged Antibodies, Bispecific, erbB-2 Receptor, gastroesophageal adenocarcinoma, Jazz, Malignant neoplasm of stomach, orphan drug designation, Overall Survival, Pharmacotherapy, Phase 2 trial, Phase 3, practice-changing, Progression-Free Survival, Zanidatamab, Zymeworks

Jazz Pharmaceuticals; Zymeworks; zanidatamab; bispecific antibody; HER2; gastroesophageal adenocarcinoma; stomach cancer; phase 2 trial; phase 3 HERIZON-GEA-01; overall survival; progression-free survival; chemotherapy; practice-changing; Orphan Drug designation

Merck Continues Cuts: 204 Employees Laid Off in New Jersey

13 hours ago talkbio0Tagged Biopharma Industry, Cautionary Warning, cost-cutting, Dosage Forms, Gardasil, global workforce reduction, Keytruda, layoffs, Merck, New Jersey, Rahway, restructuring

Merck; layoffs; New Jersey; Rahway; pharmaceutical; cost-cutting; restructuring; WARN notice; global workforce reduction; Keytruda; Gardasil; biopharma industry

Terray Therapeutics Unveils EMMI: AI-Driven Platform Revolutionizes Small Molecule Drug Discovery

17 hours ago talkbio0Tagged AI-native platform, chemical space, drug optimization, EMMI, Generative AI, Machine Learning, Nasua, small molecule drug discovery, Study models, Terray Therapeutics

Terray Therapeutics; EMMI; generative AI; small molecule drug discovery; AI-native platform; chemical space; drug optimization; biotech; machine learning; COATI model

Eli Lilly to Acquire Adverum Biotechnologies in Gene Therapy Deal; Captain T Cell Secures €20M Funding

17 hours ago talkbio0Tagged Acquisition, Adverum Biotechnologies, biotech, Captain T Cell, contingent value rights, CVR, eli lilly, financing characteristics, gene therapy, Investments, Ixo-vec, Ophthalmology specialty

Eli Lilly; Adverum Biotechnologies; Acquisition; Gene therapy; Ixo-vec; Contingent Value Rights (CVR); Ophthalmology; Captain T Cell; Financing; Biotech investment

Solve Therapeutics Raises $120M to Advance Next-Generation ADCs for Solid Tumors

17 hours ago talkbio0Tagged Antibody-Drug Conjugates, Clinical Trials, CloakLink linker technology, Merck, Neoplasms, SLV-154, SLV-324, Solid Neoplasm, Solve Therapeutics, therapeutic autologous dendritic cells, venture capital, Yosemite

Solve Therapeutics; antibody-drug conjugates; ADC; CloakLink linker technology; solid tumors; oncology; SLV-154; SLV-324; clinical trials; venture capital; Yosemite; Merck

Artios Pharma Raises $115 Million Series D to Advance DNA Damage Response Cancer Therapies

17 hours ago talkbio0Tagged alnodesertib, ART6043, Artios Pharma, Cancer Therapeutic Procedure, cellular response to DNA damage stimulus, Clinical Trials, Colorectal Carcinoma, DDR, investors, Malignant neoplasm of breast, Oncology Pipeline, Pancreatic carcinoma, Series D financing

Artios Pharma; Series D financing; DNA Damage Response (DDR); cancer therapies; alnodesertib; ART6043; oncology pipeline; pancreatic cancer; colorectal cancer; breast cancer; investors; clinical trials

Genmab Discontinues ProfoundBio-Derived ADC GEN1107 After Acquisition, Paralleling J&J’s Ambrx Buyout Area Developments

17 hours ago talkbio0Tagged AbbVie, Acquisition, Ambrx, Antibody-Drug Conjugates, Drug Development, GEN1107, Genmab, J&J, Johnson and Johnson, Neoplasms, ProfoundBio, PTK7, PTK7 protein, human

Genmab; ProfoundBio; antibody-drug conjugate (ADC); GEN1107; PTK7; Ambrx; Johnson & Johnson (J&J); oncology; drug development; biotech acquisition; AbbVie lawsuit

Sandoz Launches Tyruko (Natalizumab-Sztn), First Tysabri Biosimilar, in US After JCV Assay Delays

19 hours ago talkbio0Tagged Approved, Biological Assay, Biosimilars, JC Virus, JCV, Leukoencephalopathy, Progressive Multifocal, Multiple Sclerosis, Polpharma Biologics, Progressive, sandoz, Tyruko, Tysabri, United States Food and Drug Administration

Sandoz; Tyruko; Tysabri biosimilar; natalizumab-sztn; multiple sclerosis (MS); biosimilar launch; JCV assay; progressive multifocal leukoencephalopathy (PML); FDA approval; Polpharma Biologics

NewcelX Appoints Jeremy Shefner to Scientific Advisory Board

19 hours ago talkbio0Tagged ALS, Amyotrophic Lateral Sclerosis, AstroRx ®, Barrow Neurological Institute, Cell Therapy, Clinical Trials, Jeremy Shefner, Neurodegenerative Disorders, NewcelX, Scientific Advisory Board

NewcelX; Jeremy Shefner; Scientific Advisory Board; ALS; AstroRx; neurodegenerative disease; Barrow Neurological Institute; cell therapy; clinical trials